Antismooth Muscle and Antiactin Antibodies Are Indirect Markers of Histological and Biochemical Activity of Autoimmune Hepatitis

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP COUTO, Claudia A.
GUARDIA, Bianca D.
CANCADO, Eduardo L. R. FMUSP-HC 2014
dc.identifier.citation HEPATOLOGY, v.59, n.2, p.592-600, 2014
dc.identifier.issn 0270-9139
dc.description.abstract Reactivity and titers of autoantibodies vary during the course of autoimmune hepatitis (AIH), and some autoantibodies have been associated with disease activity and adverse outcomes after treatment. The aim of this study was to assess the autoantibody behavior in AIH and its significance as predictors of biochemical and histological remission. A total of 117 patients with AIH (mean age 18.6 [4-69] years) were evaluated and tested for autoantibodies at disease onset and successively (mean 3.2 [2-6] times) after a mean follow-up evaluation of 70 [20-185] months. Antismooth muscle (ASMA), antiliver kidney microsome type 1 (anti-LKM1), antiliver cytosol type 1 (anti-LC1), antimitochondrial, antinuclear (ANA), and antiactin antibodies (AAA) were determined at disease onset and 379 other times during the follow-up evaluation through indirect immunofluorescence in rodent tissues, HEp-2 cells, and human fibroblasts. Anti-SLA/LP were assessed 45 times in the follow-up evaluation of 19 patients using enzyme-linked immunosorbent assay (ELISA). Upon admission, AIH types 1 and 2 were observed in 95 and 17 patients, respectively. Five subjects had AIH with anti-SLA/LP as the sole markers. Patients initially negative for AAA did not develop these antibodies thereafter. ANA were detected de novo in six and three subjects with AIH types 1 and 2, respectively. After treatment, only ASMA (>1:80) and AAA (>1:40) were significantly associated with biochemical (76.9% and 79.8%) and histological features (100% and 100%) of disease activity (P<0.001). Conclusion: With the exception of ANA, the autoantibody profile does not markedly vary in the course of AIH. The persistence of high titers of ASMA and/or AAA in patients with AIH is associated with disease activity. (Hepatology 2014;59:592-600)
dc.description.sponsorship · CNPq (Research Council of Brazil)
· Alves de Queiroz Family Research Fund
· Federico Foundation
dc.language.iso eng
dc.publisher WILEY-BLACKWELL
dc.relation.ispartof Hepatology
dc.rights restrictedAccess
dc.subject.other soluble liver antigen; serum autoantibodies; f-actin; type-1; diagnosis; disease; classification; heterogeneity; childhood
dc.title Antismooth Muscle and Antiactin Antibodies Are Indirect Markers of Histological and Biochemical Activity of Autoimmune Hepatitis
dc.type article
dc.rights.holder Copyright WILEY-BLACKWELL LIM/06 LIM/07
dc.identifier.doi 10.1002/hep.26666
dc.identifier.pmid 23929663
dc.type.category original article
dc.type.version publishedVersion PORTA, Gilda:HC:ICR ABRANTES-LEMOS, Clarice P.:HC:LIM/06 CARRILHO, Flair J.:FM:MGT CANCADO, Eduardo L. R.:FM:MGT · COUTO, Claudia A.:Univ Fed Minas Gerais, Sch Med, Dept Internal Med, Belo Horizonte, MG, Brazil; Univ Fed Minas Gerais, Univ Hosp, Alfa Inst Gastroenterol, Belo Horizonte, MG, Brazil
· BITTENCOURT, Paulo L.:Portuguese Hosp, Unit Gastroenterol & Hepatol, Salvador, BA, Brazil
· GUARDIA, Bianca D.:Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil WOS:000330310300025 2-s2.0-84893692409 HOBOKEN USA
hcfmusp.relation.reference · Alvarez F., 1999, Journal of Hepatology, V31, P929, DOI 10.1016/S0168-8278(99)80297-9
· ALVAREZ F, 1985, J EXP MED, V161, P1231, DOI 10.1084/jem.161.5.1231
· Baeres M, 2002, GUT, V51, P259, DOI 10.1136/gut.51.2.259
· Ballot E, 2000, J HEPATOL, V33, P208, DOI 10.1016/S0168-8278(00)80361-X
· Bittencourt PL, 1999, AM J GASTROENTEROL, V94, P1906
· Cancado ELR, 2001, J AUTOIMMUN, V17, P223, DOI 10.1006/jaut.2001.0540
· Cassani F, 1997, HEPATOLOGY, V26, P561, DOI 10.1002/hep.510260305
· Czaja AJ, 1996, HEPATOLOGY, V24, P1068
· Czaja AJ, 2002, HEPATOLOGY, V36, P479, DOI 10.1053/jhep.2002.34944
· Czaja AJ, 2002, J HEPATOL, V37, P302, DOI 10.1016/S0168-8278(02)00182-4
· Czaja AJ, 2002, AM J GASTROENTEROL, V97, P413
· Czaja AJ, 1999, J HEPATOL, V30, P394, DOI 10.1016/S0168-8278(99)80096-8
· DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1016/0270-9139(94)90250-X
· Gayotto LCC, 2000, GED, V19, P137
· Granito A, 2006, J CLIN PATHOL, V59, P280, DOI 10.1136/jcp.2005.027367
· Gregorio GV, 2001, HEPATOLOGY, V33, P544, DOI 10.1053/jhep.2001.22131
· Gregorio GV, 2002, AUTOIMMUNITY, V35, P515, DOI 10.1080/0891693021000056721
· HOMBERG JC, 1987, HEPATOLOGY, V7, P1333, DOI 10.1002/hep.1840070626
· JOHNSON PJ, 1993, HEPATOLOGY, V18, P998, DOI 10.1002/hep.1840180435
· KRAWITT EL, 1994, AM J MED, V96, P23
· Krawitt EL, 2006, NEW ENGL J MED, V354, P54, DOI 10.1056/NEJMra050408
· Ma Y, 2002, HEPATOLOGY, V35, P658, DOI 10.1053/jhep.2002.32092
· MANNS M, 1987, LANCET, V1, P292
· Manns MP, 2010, HEPATOLOGY, V51, P2193, DOI 10.1002/hep.23584
· Mehendiratta V, 2009, CLIN GASTROENTEROL H, V7, P98, DOI 10.1016/j.cgh.2008.08.043
· Miyake Y, 2009, HEPATOL RES, V39, P241, DOI 10.1111/j.1872-034X.2008.00454.x
· Muratori L, 1998, GUT, V42, P721
· NORBERG R, 1979, EUR J BIOCHEM, V100, P575, DOI 10.1111/j.1432-1033.1979.tb04204.x
· Vergani D, 2004, J HEPATOL, V41, P677, DOI 10.1016/j.jhep.2004.08.002
· Vuppalanchi R, 2012, HEPATOL INT, V6, P379, DOI 10.1007/s12072-011-9277-8
dc.description.index MEDLINE
dc.identifier.eissn 1527-3350
hcfmusp.citation.scopus 47
hcfmusp.citation.wos 39 Brasil

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


My Account